Search research articles
Contact Us
Filters
Showing results (211-220 of 237) with videos related to
Page
of 24
Sort By:
British Journal of Haematology
|
October 31, 2009
Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma
Susan E Bates, Zhirong Zhan, Kenneth Steadman, et al.
Endocrine-Related Cancer
|
November 25, 2010
Increased uptake of [¹²³I]meta-iodobenzylguanidine, [¹⁸F]fluorodopamine, and [³H]norepinephrine in mouse pheochromocytoma cells and tumors after treatment with the histone deacetylase inhibitors
Lucia Martiniova, Shiromi M Perera, Frederieke M Brouwers, et al.
Cancer
|
October 21, 2018
Cisplatin versus cetuximab with definitive concurrent radiotherapy for head and neck squamous cell carcinoma: An analysis of Veterans Health Affairs data
Joshua M Bauml, Ravi Vinnakota, Yeun-Hee Anna Park, et al.
The Lancet. Oncology
|
December 17, 2016
Estimation of tumour regression and growth rates during treatment in patients with advanced prostate cancer: a retrospective analysis
Julia Wilkerson, Kald Abdallah, Charles Hugh-Jones, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 5, 2011
Metastatic pheochromocytoma/paraganglioma related to primary tumor development in childhood or adolescence: significant link to SDHB mutations
Kathryn S King, Tamara Prodanov, Vitaly Kantorovich, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 16, 2002
Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms
Victor Sandor, Susan Bakke, Robert W Robey, et al.
JAMA Oncology
|
January 20, 2022
Early Readout on Overall Survival of Patients With Melanoma Treated With Immunotherapy Using a Novel Imaging Analysis
Laurent Dercle, Binsheng Zhao, Mithat Gönen, et al.
Journal of the National Cancer Institute
|
September 22, 2018
Cisplatin Every 3 Weeks Versus Weekly With Definitive Concurrent Radiotherapy for Squamous Cell Carcinoma of the Head and Neck
Joshua M Bauml, Ravi Vinnakota, Yeun-Hee Anna Park, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 23, 2004
A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinoma
Susan E Bates, Susan Bakke, Min Kang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 29, 2020
Enhanced Detection of Treatment Effects on Metastatic Colorectal Cancer with Volumetric CT Measurements for Tumor Burden Growth Rate Evaluation
Michael L Maitland, Julia Wilkerson, Sanja Karovic, et al.
Page
of 24
Search research articles
Search
Showing results (211-220 of 237) with videos related to
Sort By:
Page
of 24
British Journal of Haematology
|
October 31, 2009
Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma
Susan E Bates, Zhirong Zhan, Kenneth Steadman, et al.
Endocrine-Related Cancer
|
November 25, 2010
Increased uptake of [¹²³I]meta-iodobenzylguanidine, [¹⁸F]fluorodopamine, and [³H]norepinephrine in mouse pheochromocytoma cells and tumors after treatment with the histone deacetylase inhibitors
Lucia Martiniova, Shiromi M Perera, Frederieke M Brouwers, et al.
Cancer
|
October 21, 2018
Cisplatin versus cetuximab with definitive concurrent radiotherapy for head and neck squamous cell carcinoma: An analysis of Veterans Health Affairs data
Joshua M Bauml, Ravi Vinnakota, Yeun-Hee Anna Park, et al.
The Lancet. Oncology
|
December 17, 2016
Estimation of tumour regression and growth rates during treatment in patients with advanced prostate cancer: a retrospective analysis
Julia Wilkerson, Kald Abdallah, Charles Hugh-Jones, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 5, 2011
Metastatic pheochromocytoma/paraganglioma related to primary tumor development in childhood or adolescence: significant link to SDHB mutations
Kathryn S King, Tamara Prodanov, Vitaly Kantorovich, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 16, 2002
Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms
Victor Sandor, Susan Bakke, Robert W Robey, et al.
JAMA Oncology
|
January 20, 2022
Early Readout on Overall Survival of Patients With Melanoma Treated With Immunotherapy Using a Novel Imaging Analysis
Laurent Dercle, Binsheng Zhao, Mithat Gönen, et al.
Journal of the National Cancer Institute
|
September 22, 2018
Cisplatin Every 3 Weeks Versus Weekly With Definitive Concurrent Radiotherapy for Squamous Cell Carcinoma of the Head and Neck
Joshua M Bauml, Ravi Vinnakota, Yeun-Hee Anna Park, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 23, 2004
A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinoma
Susan E Bates, Susan Bakke, Min Kang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 29, 2020
Enhanced Detection of Treatment Effects on Metastatic Colorectal Cancer with Volumetric CT Measurements for Tumor Burden Growth Rate Evaluation
Michael L Maitland, Julia Wilkerson, Sanja Karovic, et al.
Page
of 24